4/A: CONMED GC RSU Grant Corrected to 18,563 Shares

CONMED Corporation's General Counsel, Hollie K. Foust, filed an amended Form 4 to correct her Restricted Stock Unit grant to a total of 18,563 units.

Summary

• Hollie K. Foust, General Counsel & Corporate Secretary of CONMED Corporation, filed an amended Form 4 (Form 4/A).
• The amendment corrects the number of Restricted Stock Units (RSUs) granted on March 2, 2026.
• The corrected total RSU grant is 18,563 units, which includes an additional special award of 7,644 shares to the originally reported 10,919 shares.
• Each RSU represents a contingent right to receive one share of CONMED common stock, par value $0.01 per share.
• The RSUs are subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan.
• The RSUs generally vest over a three-year period: 33% after one year, 33% after the second year, and 34% after the third year from the grant date.
• The expiration date for these RSUs is March 2, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event with a slight positive tilt, as it corrects an executive's long-term incentive grant upwards, aligning their interests more strongly with shareholder value, despite the initial administrative error.

Positives

• The increased RSU grant for General Counsel Hollie K. Foust indicates a stronger alignment of executive incentives with long-term company performance.
• The grant is part of the Company's 2025 Long-Term Incentive Plan, reflecting a structured approach to executive compensation and retention.

Negatives

• The necessity of filing an amendment (Form 4/A) suggests an initial administrative error in reporting the executive's RSU grant.

Future Outlook

The RSUs are structured to vest over a three-year period, which aligns the executive's long-term incentives with the future performance and strategic objectives of the company.

Management Comments

• The RSUs are subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan.

Industry Context

StockSavvy.ai notes that RSU grants with multi-year vesting schedules are a standard component of long-term incentive compensation for executives in the medical technology and healthcare industry. This practice aims to align management's interests with shareholder value creation over an extended period. This specific amendment is an administrative correction rather than a strategic shift in compensation philosophy.

Comparison to Industry Standards

• The utilization of Restricted Stock Units (RSUs) with a three-year vesting schedule is a common and widely accepted practice in executive compensation across the medical device sector and broader S&P 500 companies, mirroring strategies employed by peers such as Medtronic, Stryker, and Zimmer Biomet.
• The specific grant size of 18,563 RSUs for a General Counsel role would typically be benchmarked against compensation data for similar positions at comparable companies within the industry, considering factors like company revenue, market capitalization, and performance. Without specific peer group data, it is not possible to definitively assess if this grant is above, below, or consistent with industry averages for similar roles.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant ties executive compensation to long-term company performance, potentially aligning management's interests with shareholder value creation.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• First tranche of RSUs (33%) will vest on March 2, 2027.
• Second tranche of RSUs (33%) will vest on March 2, 2028.
• Third tranche of RSUs (34%) will vest on March 2, 2029.

Key Dates

Keywords

CONMED Corporation, CNMD, Form 4/A, Restricted Stock Units, RSU, Executive Compensation, Hollie K. Foust, General Counsel, Insider Trading, SEC Filing